Blogs
IQWiG recommends downgrading Gilead’s Yescarta to ‘no added benefit’ – a sign of things to come for orphan drugs in Germany?
Yescarta, Gilead’s CAR-T cell therapy recently underwent a full HTA assessment in Germany after breaching the annual sales threshold for orphan drugs. Upon reassessment, Germany’s lower HTA body IQWiG recommended downgrading Yescarta’s rating in one indication to ‘no added benefit’, which is likely to negatively impact pricing negotiations.
October 5, 2023
